CTOs on the Move

Desjardins Healthcare Group

www.oms.ca

 
Desjardins Healthcare Group is a Gloucester, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oms.ca
  • 1100 Algoma Rd
    Gloucester, ON CAN K1B 0A3
  • Phone: 613.244.4690

Executives

Name Title Contact Details

Similar Companies

Injex-Equidyne Systems

Injex-Equidyne Systems is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Noir Laser Co

Noir Laser Co is a South Lyon, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karl Storz - Endoskope

Karl Storz - Endoskope is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Reva Medical

Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.

Lucira Health

Lucira Health has developed an at home COVID-19 test kit that delivers PCR quality molecular accuracy in the palm of your hand in 30 minutes or less. Our technology is transforming how we reduce the spread of infectious diseases by bringing accurate, easy-to-use self-testing into the home. This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.